NTRK1 and cancer: In addition, based on the Food and Drug Administration (FDA) approval of Larotrectinib (Vitkravi®) in 2018 as the first drug targeting NTRK1 rearrangement to be marketed and shown to have high efficacy and low toxicity in cancer treatment (14), we hypothesized that TrkA overexpression might provide an alternative target for cancer therapy with these Trk inhibitors.